402 related articles for article (PubMed ID: 16554355)
41. 8R-lisuride is a potent stereospecific histamine H1-receptor partial agonist.
Bakker RA; Weiner DM; ter Laak T; Beuming T; Zuiderveld OP; Edelbroek M; Hacksell U; Timmerman H; Brann MR; Leurs R
Mol Pharmacol; 2004 Mar; 65(3):538-49. PubMed ID: 14978232
[TBL] [Abstract][Full Text] [Related]
42. Role of the histamine system in nefopam-induced antinociception in mice.
Girard P; Pansart Y; Coppé MC; Verniers D; Gillardin JM
Eur J Pharmacol; 2004 Oct; 503(1-3):63-9. PubMed ID: 15496297
[TBL] [Abstract][Full Text] [Related]
43. Synthesis and histamine H2-agonistic activity of ring-substituted phenyl analogues of impromidine.
Buschauer A; Lachenmayr F; Schunack W
Pharmazie; 1991 Dec; 46(12):840-5. PubMed ID: 1687832
[TBL] [Abstract][Full Text] [Related]
44. Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist for the histamine H3 receptor, having a cis-cyclopropane structure.
Kazuta Y; Hirano K; Natsume K; Yamada S; Kimura R; Matsumoto S; Furuichi K; Matsuda A; Shuto S
J Med Chem; 2003 May; 46(10):1980-8. PubMed ID: 12723960
[TBL] [Abstract][Full Text] [Related]
45. Synthesis and histamine H2-receptor activity of heterocyclic impromidine analogues.
Buschauer A; Lachenmayr F; Schunack W
Pharmazie; 1992 Feb; 47(2):86-91. PubMed ID: 1353262
[TBL] [Abstract][Full Text] [Related]
46. Mutational analysis of the histamine H1-receptor binding pocket of histaprodifens.
Bruysters M; Pertz HH; Teunissen A; Bakker RA; Gillard M; Chatelain P; Schunack W; Timmerman H; Leurs R
Eur J Pharmacol; 2004 Mar; 487(1-3):55-63. PubMed ID: 15033376
[TBL] [Abstract][Full Text] [Related]
47. Histamine H1 receptors mediate vasodilation in guinea-pig ileum resistance vessels: characterization with computer-assisted videomicroscopy and new selective agonists.
Bungardt E; Buschauer A; Moser U; Schunack W; Lambrecht G; Mutschler E
Eur J Pharmacol; 1992 Oct; 221(1):91-8. PubMed ID: 1459193
[TBL] [Abstract][Full Text] [Related]
48. Identification of 4-(1H-imidazol-4(5)-ylmethyl)pyridine (immethridine) as a novel, potent, and highly selective histamine H(3) receptor agonist.
Kitbunnadaj R; Zuiderveld OP; Christophe B; Hulscher S; Menge WM; Gelens E; Snip E; Bakker RA; Celanire S; Gillard M; Talaga P; Timmerman H; Leurs R
J Med Chem; 2004 May; 47(10):2414-7. PubMed ID: 15115383
[TBL] [Abstract][Full Text] [Related]
49. Compared pharmacology of human histamine H3 and H4 receptors: structure-activity relationships of histamine derivatives.
Gbahou F; Vincent L; Humbert-Claude M; Tardivel-Lacombe J; Chabret C; Arrang JM
Br J Pharmacol; 2006 Apr; 147(7):744-54. PubMed ID: 16432504
[TBL] [Abstract][Full Text] [Related]
50. Meta-substituted aryl(thio)ethers as potent partial agonists (or antagonists) for the histamine H3 receptor lacking a nitrogen atom in the side chain.
Pelloux-Léon N; Fkyerat A; Piripitsi A; Tertiuk W; Schunack W; Stark H; Garbarg M; Ligneau X; Arrang JM; Schwartz JC; Ganellin CR
J Med Chem; 2004 Jun; 47(12):3264-74. PubMed ID: 15163206
[TBL] [Abstract][Full Text] [Related]
51. Receptor-specific functional efficacies of alkyl imidazoles as dual histamine H3/H4 receptor ligands.
Kottke T; Sander K; Weizel L; Schneider EH; Seifert R; Stark H
Eur J Pharmacol; 2011 Mar; 654(3):200-8. PubMed ID: 21237145
[TBL] [Abstract][Full Text] [Related]
52. Histaprodifens: synthesis, pharmacological in vitro evaluation, and molecular modeling of a new class of highly active and selective histamine H(1)-receptor agonists.
Elz S; Kramer K; Pertz HH; Detert H; ter Laak AM; Kühne R; Schunack W
J Med Chem; 2000 Mar; 43(6):1071-84. PubMed ID: 10737740
[TBL] [Abstract][Full Text] [Related]
53. Synthesis and pharmacological characterization of novel fluorescent histamine H2-receptor ligands derived from aminopotentidine.
Xie SX; Petrache G; Schneider E; Ye QZ; Bernhardt G; Seifert R; Buschauer A
Bioorg Med Chem Lett; 2006 Aug; 16(15):3886-90. PubMed ID: 16730977
[TBL] [Abstract][Full Text] [Related]
54. Pharmacological Characterization of Human Histamine Receptors and Histamine Receptor Mutants in the Sf9 Cell Expression System.
Schneider EH; Seifert R
Handb Exp Pharmacol; 2017; 241():63-118. PubMed ID: 28233175
[TBL] [Abstract][Full Text] [Related]
55. Structural requirements for inverse agonism and neutral antagonism of indole-, benzimidazole-, and thienopyrrole-derived histamine H4 receptor ligands.
Schneider EH; Strasser A; Thurmond RL; Seifert R
J Pharmacol Exp Ther; 2010 Aug; 334(2):513-21. PubMed ID: 20484153
[TBL] [Abstract][Full Text] [Related]
56. 4-(4-Guanidinobenzoyl)-2-imidazolones and related compounds: phosphodiesterase inhibitors and novel cardiotonics with combined histamine H2 receptor agonist and PDE III inhibitor activity.
Glass D; Buschauer A; Tenor H; Bartel S; Will-Shahab L; Krause EG
Arch Pharm (Weinheim); 1995 Oct; 328(10):709-19. PubMed ID: 8554460
[TBL] [Abstract][Full Text] [Related]
57. Novel nonimidazole histamine H3 receptor antagonists: 1-(4-(phenoxymethyl)benzyl)piperidines and related compounds.
Mikó T; Ligneau X; Pertz HH; Ganellin CR; Arrang JM; Schwartz JC; Schunack W; Stark H
J Med Chem; 2003 Apr; 46(8):1523-30. PubMed ID: 12672253
[TBL] [Abstract][Full Text] [Related]
58. Highly Potent, Stable, and Selective Dimeric Hetarylpropylguanidine-Type Histamine H
Pockes S; Wifling D; Keller M; Buschauer A; Elz S
ACS Omega; 2018 Mar; 3(3):2865-2882. PubMed ID: 30221224
[TBL] [Abstract][Full Text] [Related]
59. Structure-activity relationships of histamine H2-agonists, a new class of positive inotropic drugs.
Buschauer A; Baumann G
Agents Actions Suppl; 1991; 33():231-56. PubMed ID: 1828931
[TBL] [Abstract][Full Text] [Related]
60. A selective human H(4)-receptor agonist: (-)-2-cyano-1-methyl-3-[(2R,5R)-5- [1H-imidazol-4(5)-yl]tetrahydrofuran-2-y] methylguanidine.
Hashimoto T; Harusawa S; Araki L; Zuiderveld OP; Smit MJ; Imazu T; Takashima S; Yamamoto Y; Sakamoto Y; Kurihara T; Leurs R; Bakker RA; Yamatodani A
J Med Chem; 2003 Jul; 46(14):3162-5. PubMed ID: 12825954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
